USPTO serial 88814224
TAKING CANCER PERSONALLY
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MAYES, LAURIE ANN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TAKING CANCER PERSONALLY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Anessa O. Kramer
Anessa O. Kramer Honigman LLP39400 Woodward Avenue, Suite 101Bloomfield Hills, MI 48304-5151UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Pre-packaged medical tests kits and medical test kits to aid in the diagnosis of disease or cancer, namely, kits primarily composed of DNA probes being biochemical reagents used for detecting and analyzing molecules in protein or nucleotide arrays and also containing clinical medical reagents and antibodies for use in disease testing for clinical medical laboratory use | ACTIVE | — |
| 005 | Medical tests kits primarily comprised of medical diagnostic reagents and assays for testing body fluids | ACTIVE | — |
| 016 | Printed medical reports in the field of cancer research; printed publications, namely, newsletters and abstracts in the fields of pathology, medical testing, medical tests, diagnostic testing, oncology testing, human disease and human medical conditions; printed reports for others in the fields of pathology, medical diagnostic testing and oncology testing | ACTIVE | — |
| 041 | Providing online non-downloadable reports to others in the fields of pathology, medical diagnostic testing and oncology testing; education services, namely, providing training and on-demand on-line training in the form of courses, seminars and workshops in the fields of health, health related topics, cancer, cancer pathology, pathology, scientific testing and research services, medical testing, medical tests, diagnostic testing, oncology testing, human disease and human medical conditions; education services, namely, providing non-downloadable webinars in the fields of health, health related topics, cancer, cancer pathology, pathology, scientific testing and research services, medical testing, medical tests, diagnostic testing, oncology testing, human disease and human medical conditions; providing online, non-downloadable reports for others in the fields of medical tests, medical testing, medical research, pathology, diagnostic testing, oncology testing and human disease and medical conditions | ACTIVE | — |
| 042 | Medical research; genetic mapping for scientific purposes, namely, gene sequencing; genetic testing and sequencing for scientific purposes; molecular sequencing for scientific purposes; cancer study and analysis, cytometry, cytogenetics, cell analysis, cell preservation, clinical study and testing of cells, all being for scientific and/or research purposes; clinical study and testing of cells all being for scientific purposes; medical and scientific research information in the field of gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells for scientific or research purposes; medical and scientific research in the field of gene sequencing, molecular sequencing, cancer study and analysis, cytometry, cytogenetics, cell analysis, cell preservation, clinical study and testing of cells, and cancer; providing scientific and/or research information to others in the fields of oncology, pathology and gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells scientific testing and research services and clinical scientific testing; providing an internet website portal featuring gene sequencing, molecular sequencing, cancer study and analysis, clinical study and testing of cells all for scientific and/or research purposes; scientific and medical research information in the fields of scientific testing and research services, medical research services, and clinical scientific testing; providing cloud-based scientific and medical research information in the nature of providing temporary use of nondownloadable cloud based software for providing information to others in the field of scientific testing and research services, medical research services, and clinical scientific testing; providing temporary use of online non-downloadable software for analysis of medical test results; temporary use of online non-downloadable software for enhancement of analysis, research, and review of information pertaining to medical, scientific, genetic, testing and analysis, and information and pertaining to such testing and analysis; software as a service (SAAS) services featuring software for analysis of medical test results; non-downloadable computer software for enhancement of analysis, research, and review of information pertaining to medical, scientific, genetic, testing and analysis, and information pertaining to testing and analysis; providing medical research and scientific research information in the field of oncology; scientific testing and research services in the field of human disease and human medical conditions; providing medical research services in the field of human disease and human medical conditions; providing clinical scientific testing services and medical research and testing for scientific purposes in the field of human disease and human medical conditions; clinical laboratory research services, oncology reference laboratory services for research or scientific purposes, providing medical research information and interactive information to others in the fields of medical tests, medical testing, medical research, pathology, diagnostic testing, oncology testing and human disease and medical conditions; providing cloud-based information in the nature of providing temporary use of nondownloadable cloud based software for providing information to others in the field of scientific testing and research, medical research, and clinical scientific testing; providing online non-downloadable Internet-based software for medical testing and analysis of medical test results; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; medical and scientific research, namely, conducting clinical trials for others; conducting research and clinical trials for others relating to medical devices and pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NeoGenomics Laboratories, Inc.
- Other trademarks owned by NeoGenomics Laboratories, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 016
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named TAKING CANCER PERSONALLY
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 7, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 7, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 13, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 13, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 13, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 7, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 6, 2022 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 4, 2022 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 4, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 8, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 7, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 7, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 4, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 4, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 4, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 4, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 4, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 4, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 4, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 6, 2021 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 9, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 9, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 20, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 6, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 30, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 30, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 28, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 7, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Dec 7, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 7, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 16, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 16, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 16, 2020 | ALIE | ASSIGNED TO LIE | — |
| Oct 14, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 14, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 14, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 14, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 14, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 14, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 26, 2020 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 26, 2020 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 26, 2020 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 17, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 5, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 5, 2020 | NWAP | NEW APPLICATION ENTERED | — |